Table 2 |
|||
|
Therapeutic modulation of PRV-associated pelvic pain. |
|||
|
Group |
% Increase* |
% Relief** |
P-Value** |
|
|
|||
|
Experiment 1 |
|||
|
Saline |
392.4 ± 39.6 |
0 |
|
|
Hydroxyzine |
383.9 ± 123.9 |
2 |
P < 0.96 |
|
Diphenhydramine |
222.4 ± 74.7 |
44 |
P < 0.08 |
|
Cetirizine |
230.6 ± 52.8 |
41 |
P < 0.06 |
|
Experiment 2 |
|||
|
Saline |
431.7 ± 92.4 |
0 |
|
|
Cimetidine |
182.4 ± 43.3 |
58 |
P < 0.02 |
|
Ranitidine |
101.0 ± 37.5 |
77 |
P < 0.005 |
|
Famotidine |
167.3 ± 35.1 |
61 |
P < 0.02 |
|
Experiment 3 |
|||
|
Saline |
498.8 ± 112.7 |
0 |
|
|
Gabapentin |
371.7 ± 136.7 |
25 |
P < 0.50 |
|
L-703,606 |
116.7 ± 55.8 |
77 |
P < 0.02 |
|
Experiment 4 |
|||
|
Saline |
388.1 ± 69.5 |
0 |
|
|
Lansoprazole |
394.0 ± 44.7 |
0 |
P < 0.95 |
|
Omeprazole |
368.7 ± 68.6 |
5 |
P < 0.85 |
|
Imetit |
454.3 ± 111.8 |
0 |
P < 0.63 |
|
|
|||
|
*at PID4 relative to baseline **at PID4 relative to saline |
|||
|
Rudick et al. BMC Urology 2009 9:16 doi:10.1186/1471-2490-9-16 |
|||
